Don't Forget To
Rate This Article

AAA_Algernon - pending
Contributed Opinion

Source: Streetwise Reports (4/11/22)

Can We Make a Pill to End the Pandemic?
Source: Vision and Value (04/04/2022)

Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial
Source: Streetwise Reports (04/02/2022)

NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors.

Chen's Top Picks for Q2 2022
Source: Streetwise Reports (04/01/2022)

Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks.

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial
Source: Streetwise Reports (03/31/2022)

Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer.

Biotech Firm's Shares Double on $6B Deal
Source: Streetwise Reports (03/29/2022)

Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets.